← Leaderboards
John D Buynak
Alamx, Llc
$4,163,992
Attributed
$7,865,718
Total exposure
10
Grants
5
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.5M · FY2005–25$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$7,865,718 · 10
By mechanism
R01$6,690,356 · 3
R15$875,083 · 2
R41$297,479 · 2
P41$2,800 · 3
Top collaborators
- Sergei Vakulenko6 shared
- Konstantin V Korotkov3 shared
- Kyle H Rohde3 shared
Others in their field
Top investigators on “Antibiotics”
- Laurence H Baker · University Of Michigan At Ann Arbor$52,071,546
- Clarence Buddy Creech · Vanderbilt University Medical Center$43,812,829
- Taha E Taha · Johns Hopkins University$37,363,329
- Urs Ochsner · Crestone, Inc.$36,950,837
- Deborah T Hung · Massachusetts General Hospital$36,871,538
- Ryan Cirz · Revagenix, Inc.$35,410,554
Research focus
AntibioticsPathogenPredispositionPositioning AttributeResistanceScaffoldPharmaceutical PreparationsEvaluationModificationDesignCarbapenemsPenicillin-Binding ProteinsAntimicrobialBacteriaMediatingPropertyCarbapenemaseLibrariesVdac1 GeneInfectionHydrolysisMicrobiologyEnzymesIn Vitro
Grant awards (16)
Carbapenemase-Stable Carbapenem Antibiotics for Treatment of Multidrug-Resistant Acinetobacter baumannii Infections$773,298
R01 · FY2025 · AI
Optimization of Atypical Antimycobacterial Carbapenem Antibiotics$681,269
R01 · FY2025 · AI · contact PI
Carbapenemase-Stable Carbapenem Antibiotics for Treatment of Multidrug-Resistant Acinetobacter baumannii Infections$773,298
R01 · FY2024 · AI
Optimization of Atypical Antimycobacterial Carbapenem Antibiotics$698,616
R01 · FY2024 · AI · contact PI
Carbapenemase-Stable Carbapenem Antibiotics for Treatment of Multidrug-Resistant Acinetobacter baumannii Infections$773,298
R01 · FY2023 · AI
Optimization of Atypical Antimycobacterial Carbapenem Antibiotics$759,402
R01 · FY2023 · AI · contact PI
Carbapenemase-Stable Carbapenem Antibiotics for Treatment of Multidrug-Resistant Acinetobacter baumannii Infections$773,154
R01 · FY2022 · AI
Carbapenemase-Stable Carbapenem Antibiotics for Treatment of Multidrug-Resistant Acinetobacter baumannii Infections$784,115
R01 · FY2021 · AI
Resistance to Carbapenem Antibiotics in Acinetobacter baumannii$673,906
R01 · FY2020 · AI
Antibiotics Designed to Counter Resistant 21st Century Pathogens$436,871
R15 · FY2019 · AI · contact PI
Bicyclic beta-Lactam Antibiotics as Poor Substrates for Metallo-beta-lactamases$438,212
R15 · FY2014 · AI · contact PI
PENICILLIN-DERIVED INHIBITORS$1,243
P41 · FY2007 · RR · contact PI
PENICILLIN-DERIVED INHIBITORS$394
P41 · FY2006 · RR · contact PI
PENICILLIN-DERIVED INHIBITORS$1,163
P41 · FY2005 · RR
Dual Purpose b-Lactamase Inhibitors$137,247
R41 · FY2004 · AI
BROAD SPECTRUM BETA-LACTAMASE INHIBITORS$160,232
R41 · FY2001 · AI